Hosted on MSN1mon
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major ...
Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...
Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...
Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...
However, Johnson & Johnson has a 'savior' in its neuroscience portfolio, namely Spravato (esketamine), which is the NMDA receptor antagonist. Moreover, on January 21, 2025, the FDA approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results